Medicare Enrolled
Dr. Harsha Vyas, M.D.,
Hematology & Oncology · Dublin, GA
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Vyas from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Vyas?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Vyas
Dr. Harsha Vyas is a hematology & oncology specialist in Dublin, GA, with 18 years of NPI registration. Based on federal Medicare data, Dr. Vyas performed 212,719 Medicare services across 3,091 unique beneficiaries.
Between the years covered by Open Payments, Dr. Vyas received a total of $25,553 from 82 pharmaceutical and/or device companies across 729 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Vyas is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 18 years in practice
▲ Top 0% volume in GA
$25,553 industry payments
Medicare Practice Summary
Medicare Utilization ↗212,719
Medicare services
Top 0% in GA for hematology & oncology
3,091
Unique beneficiaries
$7
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~11,818 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron infusion (Injectafer) An intravenous injection of ferric carboxymaltose, an iron replacement medication. |
103,500 | $1 | $4 |
| Denosumab injection (Prolia/Xgeva) | 42,625 | $18 | $70 |
| Anti-nausea injection (aprepitant) | 17,944 | $1 | $6 |
| Epoetin alfa injection (Retacrit) for anemia An injection of a biosimilar form of epoetin alfa used for non-end-stage renal disease purposes. The dose administered is 1000 units. |
11,290 | $6 | $30 |
| Injection, granisetron, extended-release, 0.1 mg | 10,900 | $4 | $27 |
| Omalizumab injection (Xolair) for asthma/allergy | 6,060 | $30 | $131 |
| Epoetin alfa injection (Procrit) for anemia An injection of epoetin alfa containing 1000 units for use in patients not on end-stage renal disease (ESRD) dialysis. |
5,694 | $6 | $31 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
3,565 | $0 | $0 |
| Complete blood count (CBC) with differential An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood, including a breakdown of the different types of white blood cells. |
2,999 | $8 | $27 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
1,749 | $10 | $47 |
| Anti-nausea injection (ondansetron/Zofran) | 1,276 | $0 | $0 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
965 | $88 | $388 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
563 | $20 | $101 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
562 | $60 | $270 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
464 | $90 | $898 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
331 | $45 | $229 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
319 | $20 | $380 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
193 | $11 | $53 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 189 | $131 | $763 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
188 | $7 | $11 |
| Additional hour of intravenous infusion This code represents each additional hour of intravenous infusion beyond the initial hour for therapy, prevention, or diagnosis. |
181 | $15 | $71 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
148 | $45 | $438 |
| New patient office visit, complex (60-74 min) | 120 | $146 | $717 |
| Advance care planning consultation, first 30 min A session focused on discussing and documenting future healthcare preferences and goals. This service covers the initial 30 minutes of the planning discussion. |
112 | $60 | $293 |
| Vitamin B-12 injection An injection of vitamin B-12 (cyanocobalamin) with a dose of up to 1000 mcg. |
112 | $1 | $7 |
| Unclassified drug A medication that does not fit into standard HCPCS or CPT classification categories. |
103 | $1 | $19 |
| Zoledronic acid injection, 1 mg An injection of zoledronic acid administered at a dose of 1 mg. |
95 | $5 | $37 |
| Subcutaneous or intramuscular chemotherapy injection This procedure involves administering anti-cancer hormonal medication through an injection into the tissue under the skin or into a muscle. |
86 | $24 | $221 |
| Telephone medical discussion, 21-30 minutes A phone conversation with a nonphysician healthcare professional lasting between 21 and 30 minutes. |
75 | $23 | $70 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
75 | $1 | $3 |
| Additional hour of intravenous hydration This code represents each additional hour of intravenous fluid administration beyond the initial hour. It is used to bill for extended hydration therapy. |
59 | $9 | $44 |
| Normal saline infusion, 1000 cc Administration of 1000 cc of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater solution. |
58 | $2 | $9 |
| On-body injector for subcutaneous injection A device is applied to the skin to automatically deliver a medication injection under the skin. |
40 | $13 | $65 |
| Urinalysis, manual A manual laboratory examination of a urine sample to check for various substances and cells. |
33 | $3 | $12 |
| Telephone medical discussion, 11-20 minutes A phone conversation with a nonphysician healthcare professional lasting between 11 and 20 minutes. |
33 | $16 | $47 |
| Stool test for blood to screen for colon tumors A test that analyzes a stool sample to detect hidden blood, which is used to screen for colon tumors. |
13 | $4 | $15 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
49.5% high complexity
48.0% medium
2.6% routine
Industry Payment Transparency
Open Payments through 2024 ↗$25,553
Total received (2018-2024)
Avg $3,650/year across 7 years
Top 15% in GA for hematology & oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
82
Companies
729
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$15,787 (61.8%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$8,188 (32.0%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$1,578 (6.2%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$2,001
2023
$4,552
2022
$3,380
2021
$4,587
2020
$4,059
2019
$3,147
2018
$3,826
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
PFIZER INC.
$260
Incyte Corporation
$218
Coherus Biosciences Inc.
$128
Heron Therapeutics, Inc.
$124
ASD Specialty Healthcare, LLC
$109
BeiGene USA, Inc.
$105
Merck Sharp & Dohme LLC
$98
Celgene Corporation
$94
GENZYME CORPORATION
$84
Astellas Pharma US Inc
$80
AstraZeneca Pharmaceuticals LP
$76
Mirati Therapeutics, Inc.
$60
Regeneron Healthcare Solutions, Inc.
$57
Novartis Pharmaceuticals Corporation
$53
ARRAY BIOPHARMA INC
$48
Lilly USA, LLC
$45
Aveo Pharmaceuticals, Inc.
$41
Genentech USA, Inc.
$41
Janssen Biotech, Inc.
$40
Gilead Sciences, Inc.
$39
IntrinsiQ Specialty Solutions, Inc.
$39
Takeda Pharmaceuticals U.S.A., Inc.
$33
Daiichi Sankyo Inc.
$30
Eisai Inc.
$25
Ipsen Biopharmaceuticals, Inc
$22
Tempus AI, Inc
$20
ABBVIE INC.
$16
Pharmacosmos Therapeutics Inc.
$14
Top 3 companies account for 30.3% of 2024 payments
All-time payments by company (2018-2024) ›
AstraZeneca Pharmaceuticals LP
$4,287
Novartis Pharmaceuticals Corporation
$3,307
E.R. Squibb & Sons, L.L.C.
$1,847
Genentech USA, Inc.
$1,071
Mirati Therapeutics, Inc.
$949
Amgen Inc.
$899
Janssen Biotech, Inc.
$894
Athenex Pharmaceutical Division, LLC
$867
Daiichi Sankyo Inc.
$755
Partner Therapeutics, Inc.
$692
Seagen Inc.
$576
Merck Sharp & Dohme LLC
$575
Merck Sharp & Dohme Corporation
$573
Celgene Corporation
$524
PFIZER INC.
$470
Astellas Pharma US Inc
$447
Incyte Corporation
$381
GENZYME CORPORATION
$379
Fresenius Kabi USA, LLC
$370
Regeneron Healthcare Solutions, Inc.
$344
ASD Specialty Healthcare, LLC
$339
Spectrum Pharmaceuticals Inc.
$292
AbbVie, Inc.
$288
Coherus Biosciences Inc.
$246
Heron Therapeutics, Inc.
$215
GlaxoSmithKline, LLC.
$213
BeiGene USA, Inc.
$212
Lilly USA, LLC
$212
Gilead Sciences, Inc.
$201
Takeda Pharmaceuticals U.S.A., Inc.
$188
Exelixis Inc.
$166
Ipsen Biopharmaceuticals, Inc
$162
Rigel Pharmaceuticals, Inc.
$159
COMSORT, Inc
$150
Karyopharm Therapeutics Inc.
$149
Foundation Medicine, Inc.
$135
Eisai Inc.
$132
EISAI INC.
$131
Regeneron Pharmaceuticals, Inc.
$108
ASD SPECIALTY HEALTHCARE, LLC
$98
ARRAY BIOPHARMA INC
$97
Pharmacosmos Therapeutics Inc.
$95
Dendreon Pharmaceuticals LLC
$80
Puma Biotechnology, Inc.
$79
Boehringer Ingelheim Pharmaceuticals, Inc.
$78
Clovis Oncology, Inc.
$71
Pharmacyclics LLC, An AbbVie Company
$68
AMAG Pharmaceuticals, Inc.
$68
Bayer HealthCare Pharmaceuticals Inc.
$58
Kite Pharma, Inc.
$53
Alexion Pharmaceuticals, Inc.
$53
CTI BioPharma Corp.
$46
Grifols USA, LLC
$42
SOBI, INC
$42
Aveo Pharmaceuticals, Inc.
$41
IntrinsiQ Specialty Solutions, Inc.
$39
PUMA BIOTECHNOLOGY, INC.
$38
Sun Pharmaceutical Industries Inc.
$34
TG THERAPEUTICS, INC.
$33
Myriad Genetic Laboratories, Inc.
$32
Verastem, Inc.
$31
Seattle Genetics, Inc.
$25
AVEO Pharmaceuticals, Inc.
$24
Myovant Sciences Inc.
$24
Helsinn Therapeutics (U.S.), Inc.
$24
SANOFI-AVENTIS U.S. LLC
$20
Tempus AI, Inc
$20
Emmaus Medical, Inc.
$20
Blueprint Medicines Corporation
$19
ImmunoGen, Inc.
$19
Janssen Scientific Affairs, LLC
$17
Deciphera Pharmaceuticals Inc.
$17
Teva Pharmaceuticals USA, Inc.
$16
ABBVIE INC.
$16
Stemline Therapeutics Inc.
$16
SERVIER PHARMACEUTICALS LLC
$15
Janssen Pharmaceuticals, Inc
$15
G1 Therapeutics, Inc.
$14
MorphoSys, US Inc.
$14
EMD Serono, Inc.
$14
Adaptive Biotechnologies Corporation
$12
Array BioPharma Inc.
$11
Top 3 companies account for 36.9% of all-time payments
Associated products mentioned in payments ›
ADCETRIS · AKYNZEO · ALIMTA · Alecensa · Aranesp · Avastin · BENDEKA · BLENREP · BOSULIF · BRAFTOVI · BRUKINSA · Bavencio · Blincyto · Braftovi · CALQUENCE · CINVANTI · COSELA · CYRAMZA · Cabometyx · Columvi · Copiktra · DARZALEX · DOPTELET · Doptelet · ELIQUIS · ELITEK · ELREXFIO · EMEND · ERLEADA · EVENITY · Elahere · Endari · Enhertu · Erleada · FASENRA · FASLODEX · FERAHEME · FOTIVDA · FOUNDATIONONE · GAVRETO · GAZYVA · GILOTRIF · Gamunex-C · Gazyva · HYQVIA · IBRANCE · ICLUSIG · IMBRUVICA · IMFINZI · INJECTAFER · INLYTA · Imbruvica · JAKAFI · JEVTANA · KANJINTI · KEYTRUDA · KISQALI · KRAZATI · Kyprolis · LEUKINE · LIBTAYO · LORBRENA · LUMAKRAS · LYNPARZA · Lenvima · Leukine · MEKINIST · MONJUVI · MONOFERRIC · NERLYNX · NINLARO · Nexavar · Nplate · Nubeqa · OJJAARA · ONUREG · OPDIVO · OPDUALAG · ORGOVYX · Onivyde · Oral Paclitaxel · Orserdu · PADCEV · PEMAZYRE · PIQRAY · PRECISETUMOR · PROMACTA · PROVENGE · Padcev · Perjeta · Polivy · Pomalyst · Prolia · QINLOCK · REBLOZYL · ROLVEDON · Revlimid · Rezlidhia · Rubraca · SANDOSTATIN · SARCLISA · SCEMBLIX · SHINGRIX · SOMATULINE DEPOT · SUTENT · Somatuline Depot · Stimufend · Stivarga · TAGRISSO · TASIGNA · TECENTRIQ · TECVAYLI · TIBSOVO · TIVDAK · TUKYSA · Tavalisse · Trodelvy · UKONIQ · ULTOMIRIS · Udenyca · VENCLEXTA · VERZENIO · VOTRIENT · Vectibix · Venclexta · Vitrakvi · Vonjo · XALKORI · XARELTO · XGEVA · XPOVIO · XTANDI · Xospata · Xtandi · Yescarta · ZEJULA · ZYTIGA · clonoSEQ
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (62%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Hematology & oncology specialists within 10 mi
2
Per 100K population
4.0
County median income
$49,705
Nearest hospital
FAIRVIEW PARK HOSPITAL
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Vyas is a mixed practice specialist, with above-average Medicare volume (top 0% in GA), with low-engagement industry engagement in the top 15% of GA peers, with 18 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Vyas experienced with iron infusion (injectafer)?
Based on Medicare claims data, Dr. Vyas performed 103,500 iron infusion (injectafer) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Vyas receive payments from pharmaceutical companies?
Yes. Dr. Vyas received a total of $25,553 from 82 companies across 729 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Vyas's costs compare to other hematology & oncology specialists in Dublin?
Dr. Vyas's average Medicare payment per service is $7. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Vyas) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncology Specialists in Dublin
Browse hematology & oncology specialists in Dublin ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in GA
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in GA
Which GA hematology & oncology specialists receive the most from drug and device companies.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
By company
E.R. Squibb & Sons, L.L.C. Payments to Doctors
See all physicians who received payments from E.R. Squibb & Sons, L.L.C.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology